&w=3840&q=100)
NSE IPO: 6 reasons why it's time for National Stock Exchange to go public
The time has come for the NSE to embrace public markets, and the reasons are compelling—both from a governance and a market development perspective.
1. Broad-based ownership: The case for democratisation
With over 100,000 shareholders, NSE already boasts a more widely held ownership base than many constituents of the Nifty 500. This broad base reflects deep investor interest and sets the stage for an even broader and more democratic participation, should NSE list. In a country where equity participation is growing rapidly, it is only fair that every Indian investor gets the opportunity to own a share of this national institution through transparent public markets.
2. Corporate governance
NSE has consistently set benchmarks for governance that are on par, if not ahead, of most listed companies in India. Its investor presentations are a model of clarity and disclosure, surpassing the standards seen in several Nifty and Sensex companies. Transparency in communication, accountability to stakeholders, and robust risk management practices position NSE as a natural fit for the listed space.
3. Leadership compensation: The misplaced debate
Concerns around executive remuneration at NSE are significantly overblown. The CEO, Mr. Ashish Kumar Chauhan, was remunerated around ₹12 crore in the last fiscal, a figure that is modest by any benchmark, domestic or overseas, especially given the scale and importance of the institution. Moreover, a substantial portion is deferred variable pay. Comparatively, leaders at other large financial institutions—receive far higher compensation, often supplemented with generous ESOPs, which NSE does not offer.
4. The need for quality equity paper: A national asset for the masses
NSE is a national asset. Today, an enormous amount of investor capital is being funnelled into sub-par businesses at lofty valuations, in part due to the shortage of high-quality, blue-chip equity opportunities. Listing NSE would provide Indian investors with a chance to participate in the growth of a fundamentally sound, cash-generating institution—channelling savings into assets that genuinely deserve capital and boosting overall market health.
5. Bringing price discovery into the sunlight
Despite not being listed, price discovery for NSE shares occurs in a shadowy parallel market. This environment is rife with inefficiencies, poor liquidity, delivery defaults, and price renegotiations—all of which harm investor confidence and undermine orderly market functioning. Listing NSE would eliminate these risks, bringing transparency, better regulation, and true price discovery to one of the country's most important assets. For the largest and most systemically important unlisted company to be denied a formal platform for price discovery is, frankly, an irony that needs to be addressed.
6. Regulatory concerns are not a showstopper
Some argue that issues around clearing corporations or conflict management are reasons for delay. Yet, two other exchanges in the country are listed, and similar questions have been managed in their cases—albeit imperfectly. Regulatory evolution is ongoing, and any remaining hurdles can and should be addressed pragmatically as part of the listing process, not as a reason for indefinite delay.
All said, the listing of the National Stock Exchange is not just a matter of institutional pride—it is an imperative for the continued evolution, transparency, and democratisation of India's capital markets.
The market regulator, who keeps investor interest above everything else, has played an enabling role to facilitate fair price discovery and broad-based ownership of national assets. The NSE, by every objective metric, is ready for the next leap. It is time to bring this national asset into the sunlight, for the benefit of all Indian investors.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 minutes ago
- Economic Times
PB Fintech Q1 Results: Cons PAT surges 41% YoY to Rs 85 crore, revenue jumps 33%
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Mint
12 minutes ago
- Mint
Market holds nerves on hope of Taco trade, rupee lowest in 5 months
A surprise 25% tariff imposed by the US on Indian exports, coupled with threats of penalties for buying Russian oil, rattled equity market investors early in the session on Thursday. However, strong buying helped the market stabilize, reflecting cautious optimism over tariff easing—a potential policy change that analysts call a 'Taco trade', shorthand for 'Trump always chickens out'. The benchmark Nifty 50 opened 200 points lower and then recovered, but eventually ended the session 86 points lower than the previous close at 24,768.35. The day, the last Thursday of the month, also marked the expiration of the July derivatives series, leading traders to roll over positions amid the ongoing uncertainty. "Today's market action suggests that investors are bracing for a Taco trade," said Nilesh Shah, managing director at Kotak Mahindra AMC. 'The market is hoping that Trump will reverse the tariff proposal keeping in mind the strategic interests of both the US and India. But whether or not that will happen is anybody's guess, given the mercurial nature of Potus,' Shah said. 'If indeed he does a Taco trade will play out, if not the volatility will increase," he added. The bellwether Nifty 50 closed above its crucial support zone of 24,500-24,600 points, which has held for many sessions, indicating that the markets are not overly worried. But if the uncertainty on tariffs persists, a breaching of this level cannot be ruled out, said Akshay Chinchalkar, head of research at Axis Securities. Chinchalkar added that until Nifty 50 tops the resistance point of 25,020, it is likely to remain in the lower band of 24,450 -25,020. 'Mixed global cues and lack of immediate details (on US tariffs) made traders adopt a wait-and-watch stance on Thursday,' said Trivesh D., chief operating officer at Tradejini. The markets had baked in a tariff of 15-20%, so the 25% levy--coupled with an unspecified penalty for buying Russian arms and energy--had led to an expectation of at least a one percentage fall in the indices, analysts said. The more benign decline has increased hopes of a bounce-back. "I think we are looking at the 24,500 support holding and can see a potential bounce toward 25,500 next month if that plays out," said Kruti Shah, quant analyst at Equirus. Though the equity market held its nerve, the rupee continued with its fall against the US dollar from Wednesday which marked its biggest decline in five months. The local currency ended 17 paise lower at 87.6 to the dollar on Thursday. "Due to Trump's nasty surprise, there is concern on the current account, which has queered the pitch for the rupee," said Sujan Hajra, chief economist at Anand Rathi. Hajra said the worst case is for the rupee to weaken by another 2.0-2.5 units in the short-term before the Reserve Bank of India intervenes. Foreign institutional investors have continued to sell shares through the month. They net sold shares worth ₹ 5,538.19 crore on Thursday, while they sold ₹ 1,236 crore worth of index futures. The market may react on sentiment in the short-term, but it is 'unlikely to experience a major correction or trigger panic,' said Siddarth Bhamre, head of research (institutional equities) at Asit C. Mehta Investment Intermediaries Ltd. Among sectoral indices, the Nifty Pharma fell the most, by 1.3%, followed by the Nifty Metal Index that declined 1.2%. The new US tariffs are likely to have a limited impact on corporate earnings, and it is primarily likely to hit a small set of export-oriented companies, who may have to absorb part of the price increase, said Geroge Thomas, fund manager at Quantum Mutual Fund. These companies represent only a small portion of the market and will, thus, not impact the overall earnings, he added. A few sectors such as pharmaceuticals and textiles may initially face pressure on their margins, as companies may have to bear a small part of the tariff cost at first before they can pass it on to their customers, but there will be no structural impact, said Vikas Khemani, founder of Carnelian Asset Advisors. Khemani said he sees the overall impact to be limited since the tariff for India was lower than that on China, and as customers rarely switch supply channels solely due to price factors, especially in the 'sticky sectors'. 'We estimate a 30-50% of the burden of tariff to fall on Indian exporters and the rest on US importers and consumers. However, any weakening of the rupee would partially offset the margin pressures of Indian exporters in rupee terms,' a report of Anand Rathi Research had said on Wednesday. Tariffs at this level could shrink India's big merchandise trade surplus with the US, its top export market, the report said. India's GDP growth projection could take a mild hit of 30-40 basis points if the tariff remains at 25%, the Anand Rathi report added. The country's GDP growth is projected at 6.5% for FY26, as per the Reserve Bank of India.
Mint
12 minutes ago
- Mint
Sun Pharma net profit falls on US antitrust settlement, drug impairment costs
Sun Pharmaceutical Industries Ltd's revenue from operations for the April-June period beat Street expectations to rise 9.4% year-on-year to ₹ 13,851 crore. However, the drugmaker's net profit fell on exceptional items including settlement costs in a pricing antitrust litigation in the US and discontinuing clinical studies on one of its drugs. The company posted a net profit of ₹ 2,279 crore in Q1FY26, down 20% from a year earlier. A healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins during the quarter. The drugmaker has been banking on both segments to drive growth in FY26. Its adjusted net profit, excluding the exceptional items, for Q1FY26 was ₹ 2,996 crore, up 5.7%, Sun Pharma said in an exchange filing on Thursday. "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance,' chairman and managing director Dilip Shanghvi said in the statement. Sun Pharma and its subsidiary Taro Pharmaceuticals agreed to pay $200 million to settle a generics antitrust pricing litigation in the US earlier this month. The company also announced that it was discontinuing studies on its drug candidate SCD-044 for atopic dermatitis, after the drug did not meet primary objectives in phase-2 trials. A Bloomberg poll of 14 brokerages had estimated the firm's revenue to be ₹ 13,699 crore, and its profit after tax at ₹ 3,042 crore. Sun Pharma reported an Ebitda (earnings before interest, taxes, depreciation, and amortisation) of ₹ 4,302 crore, up 19.2%, with the margin expanding to 31.1%. The increase in Ebitda margin was on account of improvement in raw material costs, as well as higher sales of its global specialty products and domestic branded formulations, the company's chief financial officer Jayashree Satagopan told investors in a post-earnings call on Thursday evening. Sun Pharma's share price settled 2% lower at ₹ 1,700 on the NSE on Thursday. Sun Pharma's domestic business saw robust double-digit growth, maintaining its momentum. India formulation sales rose 13.9% YoY to ₹ 4,721 crore. The growth was driven by an increase in volume as well as new product launches, as opposed to the overall Indian pharmaceutical market which is largely growing on the back of price increases. The company saw an uptick in its global specialty or innovative medicines sales, rising 16.9% to $311 million. This segment accounted for 19.3% of its quarterly sales and drove up the overall US sales. The company reported overall US sales of $473 million, up 1.4%. 'This growth is driven by our innovative medicines portfolio with all of our growth products contributing, including Ilumya, Cequa, Winlevi, and Odomzo, but offset by decline in our generics business due to additional competition in certain products,' Richard Ascroft, North America chief executive officer, told investors, adding that the company is seeing contingent pricing pressure from blood cancer drug Revlimid, which is set to lose exclusivity next year. The US accounted for 29.3% of consolidated sales for the quarter. Sun Pharma launched its drug for severe alopecia areata, Leqselvi, in the US during the quarter. 'We're very encouraged by early results, we've seen good receptivity with healthcare professionals and patients, and we already have our initial commercial prescriptions,' said Ascroft. Sun Pharma is gearing up for the launch of cancer drug Unloxcyt in the second half of FY26, the company said.
